From the Journals

Excellent outcome of Ross procedure after 2 decades


 

DISCLOSURES:

Mr. Notenboom has disclosed no relevant financial relationships. Co-author Fabio De Robertis, MD, department of cardiothoracic surgery and transplantation, Royal Brompton & Harefield Hospitals, London, received nonfinancial support from Edwards Lifescience for travel and personal fees from Bristol Myers Squibb for consulting outside the submitted work, and has a service agreement with Medtronic U.K., which paid a fee to the Royal Brompton & Harefield Hospitals Charity Fund.

Editorial co-author Kaneko received personal fees from Edwards Lifesciences, Medtronic, Abbott, and Johnson & Johnson outside the submitted work; Ouzounian received personal fees from Medtronic, Edwards Lifesciences, and Terumo Aortic outside the submitted work.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Optimal antiplatelet regimen in ‘bi-risk’ ACS?
MDedge Cardiology
Hopeful insights, no overall HFpEF gains from splanchnic nerve ablation: REBALANCE-HF
MDedge Cardiology
New tool to guide transcatheter aortic valve replacement
MDedge Cardiology
Durable LVAD for advanced HF still underutilized
MDedge Cardiology
Trilogy TAVR safe, effective in aortic regurgitation
MDedge Cardiology
Low-risk TAVR studies: Divergent long-term results
MDedge Cardiology
Drug-eluting resorbable scaffold beats angioplasty for infrapopliteal artery disease
MDedge Cardiology
Second pig heart recipient dies
MDedge Cardiology
Drug-coated balloon beats conventional angioplasty for high-risk patients with in-stent restenosis
MDedge Cardiology
Short aspirin therapy noninferior to DAPT for 1 year after PCI for ACS
MDedge Cardiology